Melatonina
Anno: 1998
-
Riferimento:Lancet. 1998 Oct 24;352(9137):1389-90.Azione della melatonina:No abstract available.Target:No abstract available.
-
Riferimento:Lancet. 1998 Oct 24;352(9137):1389.Azione della melatonina:No abstract available.Target:No abstract available.
-
Riferimento:Comp Biochem Physiol A Mol Integr Physiol. 1998 Feb;119(2):493-501.Azione della melatonina:Protects bone marrow, lymphoid tissues from damaging effect of cytotoxic drugs.Target:100 μg melatonin daily intraperitoneally injected.
Anno: 1999
-
Riferimento:Life Sci. 1999;65(4):415-20.Azione della melatonina:Melatonin (1 nM) inhibits MCF-7 cell proliferation with an increased expression of p21WAF1 protein mediated by the p53 pathway.Target:p53/p21WAF1.
-
Titolo: Meditation and prostate cancer: integrating a mind/body intervention with traditional therapiesRiferimento:Semin Urol Oncol. 1999 May;17(2):111-8. Review.Azione della melatonina:Association between meditation practice and levels of melatonin which can influence breast and prostate tumors.Target:Psychoneuroimmunology.
-
Riferimento:J Pineal Res. 1999 Apr;26(3):169-73Azione della melatonina:Melatonin (orally at 20 mg/day) may contribute to the realization of chemotherapy in metastatic cancer patients.Target:Thrombocytopenia.
-
Riferimento:Adv Exp Med Biol. 1999;460:407-9.Azione della melatonina:(No abstract available).Target:(No abstract available).
-
Riferimento:Adv Exp Med Biol. 1999;460:345-62. Review.Azione della melatonina:No abstract available.Target:No abstract available.
-
Riferimento:Natl Toxicol Program Tech Rep Ser. 1999 Aug;489:1-148.Azione della melatonina:No evidence that magnetic fields promoted the development of mammary gland neoplasms initiated by the administration of dimethylbenzanthracene.Target:DMBA/ELF 50 Hz
-
Riferimento:Environ Health Perspect. 1999 Feb;107 Suppl 1:145-54. Review.Azione della melatonina:Melatonin-breast cancer and EMF-breast cancer hypotheses.Target:Electromagnetic fields (EMF).